WO2007079999A3 - Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege - Google Patents
Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege Download PDFInfo
- Publication number
- WO2007079999A3 WO2007079999A3 PCT/EP2006/068323 EP2006068323W WO2007079999A3 WO 2007079999 A3 WO2007079999 A3 WO 2007079999A3 EP 2006068323 W EP2006068323 W EP 2006068323W WO 2007079999 A3 WO2007079999 A3 WO 2007079999A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- signal transduction
- modulators
- transduction paths
- pyridopyrazine derivatives
- pyridopyrazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0618451-0A BRPI0618451A2 (pt) | 2005-11-11 | 2006-11-10 | derivados de piridopirazina, seu uso, composição farmacêutica e estojo |
EP06849272.7A EP1962854B1 (de) | 2005-11-11 | 2006-11-10 | Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege |
PL06849272T PL1962854T3 (pl) | 2005-11-11 | 2006-11-10 | Pochodne pirydopirazyny i ich zastosowanie jako modulatorów szlaków transdukcji sygnału |
ES06849272.7T ES2543962T3 (es) | 2005-11-11 | 2006-11-10 | Derivados de piridopirazina y su uso como moduladores de las vías de transducción de señales |
CN200680047112.6A CN101330918B (zh) | 2005-11-11 | 2006-11-10 | 吡啶并吡嗪衍生物及其作为信号转导途径调节剂的应用 |
JP2008539444A JP5448450B2 (ja) | 2005-11-11 | 2006-11-10 | ピリドピラジン誘導体及びその使用 |
AU2006334721A AU2006334721B2 (en) | 2005-11-11 | 2006-11-10 | Pyridopyrazine derivatives and use thereof as modulators of the signal transduction paths |
CA002628186A CA2628186A1 (en) | 2005-11-11 | 2006-11-10 | Pyridopyrazine derivatives and the use thereof as medicaments in pi3k related diseases |
RU2008123219/15A RU2487713C2 (ru) | 2005-11-11 | 2006-11-10 | Фармацевтическая композиция и способ лечения или профилактики физиологических и/или патофизиологических состояний, ассоциированных с ингибированием киназ pi3k, у млекопитающих |
IL191160A IL191160A (en) | 2005-11-11 | 2008-04-30 | Use of pyrido [3,2- b] pyrazine-6-yl urine urine for the preparation of drugs to treat diseases caused by the enzyme pi3k inhibition. |
NO20082509A NO20082509L (no) | 2005-11-11 | 2008-06-03 | Pyridopyrazinderivater og deres anvendelse |
HK09102357.4A HK1125823A1 (zh) | 2005-11-11 | 2009-03-12 | 吡啶並吡嗪衍生物及其作為信號轉導途徑調節劑的應用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73570705P | 2005-11-11 | 2005-11-11 | |
EP05024692.5 | 2005-11-11 | ||
EP05024692A EP1790342A1 (de) | 2005-11-11 | 2005-11-11 | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
US60/735,707 | 2005-11-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007079999A2 WO2007079999A2 (de) | 2007-07-19 |
WO2007079999A3 true WO2007079999A3 (de) | 2007-10-04 |
Family
ID=36424666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/068323 WO2007079999A2 (de) | 2005-11-11 | 2006-11-10 | Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege |
Country Status (21)
Country | Link |
---|---|
US (1) | US8937068B2 (de) |
EP (2) | EP1790342A1 (de) |
JP (1) | JP5448450B2 (de) |
KR (1) | KR101473662B1 (de) |
CN (1) | CN101330918B (de) |
AR (1) | AR056216A1 (de) |
AU (1) | AU2006334721B2 (de) |
BR (1) | BRPI0618451A2 (de) |
CA (1) | CA2628186A1 (de) |
ES (1) | ES2543962T3 (de) |
HK (1) | HK1125823A1 (de) |
IL (1) | IL191160A (de) |
NO (1) | NO20082509L (de) |
NZ (1) | NZ595879A (de) |
PL (1) | PL1962854T3 (de) |
RU (1) | RU2487713C2 (de) |
SG (1) | SG10201401061XA (de) |
TW (1) | TWI423973B (de) |
UA (1) | UA95464C2 (de) |
WO (1) | WO2007079999A2 (de) |
ZA (1) | ZA200803867B (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090118139A1 (en) * | 2000-11-07 | 2009-05-07 | Caliper Life Sciences, Inc. | Microfluidic method and system for enzyme inhibition activity screening |
WO2007054556A1 (de) * | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
US9139630B2 (en) | 2006-07-11 | 2015-09-22 | Rutgers, The State University Of New Jersey | Compositions and methods for preparing recombinant MG53 and methods for optimizing same |
US7893066B2 (en) * | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
EP1990342A1 (de) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazin-Derivate sowie Herstellungs- und Verwendungsverfahren dafür |
WO2009073808A2 (en) * | 2007-12-04 | 2009-06-11 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods to modulate cell membrane resealing |
US8399483B2 (en) | 2007-12-21 | 2013-03-19 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
WO2010045374A1 (en) * | 2008-10-15 | 2010-04-22 | Gilead Palo Alto, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
WO2010052448A2 (en) * | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
WO2011142744A1 (en) * | 2010-05-11 | 2011-11-17 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
WO2012061793A1 (en) | 2010-11-05 | 2012-05-10 | Trimedicine, Inc. | Serum mg53 as a diagnostic marker for tissue injury |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
EP2508184A1 (de) * | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazinderivate und ihre Verwendungen |
JP5792128B2 (ja) * | 2011-07-29 | 2015-10-07 | 富士フイルム株式会社 | 1,5−ナフチリジン誘導体又はその塩 |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
WO2014109414A1 (ja) | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
MX2016012368A (es) | 2014-03-26 | 2017-02-23 | Astex Therapeutics Ltd | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
SI3353177T1 (sl) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Triciklični heterocikli za zdravljenje raka |
CN107619388A (zh) * | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
WO2018237190A1 (en) | 2017-06-22 | 2018-12-27 | City Of Hope | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF |
WO2019238933A1 (en) * | 2018-06-15 | 2019-12-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity |
CN111892597B (zh) * | 2020-09-01 | 2023-07-25 | 山西天宏达安医药科技有限公司 | 一种喹喔啉基吡啶并吡嗪类化合物及其制备方法与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
WO2004104003A1 (de) * | 2003-05-23 | 2004-12-02 | Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
WO2004104002A1 (de) * | 2003-05-23 | 2004-12-02 | Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als kinase-inhibitoren |
WO2005007099A2 (en) * | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
WO2007054556A1 (de) * | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3209004A (en) | 1963-05-17 | 1965-09-28 | American Home Prod | 3, 6-diamino-n-(2, 2-dialkoxyethyl) pyrido[2, 3-b] pyrazine-2-carboxamides |
US3180868A (en) | 1963-07-24 | 1965-04-27 | American Home Prod | 3, 6-diamino-n-(substituted)pyrido[2, 3-b]-pyrazine-2-carboxamides |
US3809695A (en) | 1967-04-19 | 1974-05-07 | Degussa | 2,6-dichloro-3-nitro-pyridine |
JPS5053394A (de) | 1973-09-20 | 1975-05-12 | ||
US4082845A (en) | 1977-04-25 | 1978-04-04 | Merck & Co., Inc. | 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DE69600385T2 (de) | 1995-03-28 | 1998-12-17 | Sumitomo Chemical Co | Verfahren zur Herstellung von Aminonitropyridinen |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
JP4403482B2 (ja) | 1997-12-22 | 2010-01-27 | バイエル コーポレイション | 置換複素環尿素合成のための中間体およびその製造方法 |
US6103903A (en) | 1998-02-26 | 2000-08-15 | Neurogen Corporation | 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
AU2180500A (en) | 1998-12-15 | 2000-07-03 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
KR20010099877A (ko) | 1998-12-22 | 2001-11-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 배합물 화학요법 |
IL152275A0 (en) | 2000-04-25 | 2003-05-29 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
IL153817A0 (en) | 2000-07-19 | 2003-07-31 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
ATE345129T1 (de) | 2000-10-12 | 2006-12-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
HUP0400048A3 (en) | 2001-05-05 | 2008-10-28 | Smithkline Beecham Plc | N-aroyl cyclic amines and pharmaceutical compositions containing them |
CN101851173A (zh) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
JP4445753B2 (ja) | 2002-01-29 | 2010-04-07 | グラクソ グループ リミテッド | アミノピペリジン誘導体 |
US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
US20060142178A1 (en) | 2002-04-08 | 2006-06-29 | Barnett Stanley F | Method of treating cancer |
EP1496906A4 (de) | 2002-04-08 | 2006-05-03 | Merck & Co Inc | Hemmer der akt aktivität |
WO2003086394A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2004005472A2 (en) | 2002-07-02 | 2004-01-15 | Southern Research Institute | Inhibitors of ftsz and uses thereof |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
MXPA05003477A (es) | 2002-10-03 | 2005-07-22 | Targegen Inc | Agentes vasculo-estaticos y metodos de uso de los mismos. |
US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
JP2006515847A (ja) | 2002-12-13 | 2006-06-08 | ニューロジェン・コーポレーション | カプサイシン受容体調節剤としてのカルボン酸、ホスフェート又はホスホネート置換キナゾリン−4−イルアミン類縁体 |
BRPI0410998A (pt) | 2003-06-05 | 2006-07-04 | Zentaris Gmbh | derivados de indol com efeito de indução de apoptose |
SE0302304D0 (sv) | 2003-08-27 | 2003-08-27 | Astrazeneca Ab | Novel compounds |
WO2005023771A1 (ja) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
WO2005023807A2 (en) | 2003-09-09 | 2005-03-17 | Neurogen Corporation | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
US7592340B2 (en) | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
AU2005209257A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
DE102004017932A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US20050256309A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
WO2006002047A2 (en) | 2004-06-15 | 2006-01-05 | Glaxo Group Limited | Antibacterial agents |
GB0413953D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
GB0413955D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
WO2006014580A1 (en) | 2004-07-08 | 2006-02-09 | Glaxo Group Limited | Antibacterial agents |
JP2008506695A (ja) | 2004-07-13 | 2008-03-06 | グラクソ グループ リミテッド | 抗細菌剤 |
US20070270417A1 (en) | 2004-07-22 | 2007-11-22 | Glaxo Group Limited | Antibacterial Agents |
DE602005024151D1 (de) | 2004-08-02 | 2010-11-25 | Glaxo Group Ltd | Antibakterielle mittel |
US20070161627A1 (en) | 2004-08-09 | 2007-07-12 | Miller William H | Antibacterial agents |
DE102004041163A1 (de) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
EP1786812B1 (de) | 2004-09-03 | 2011-11-09 | Merck Serono SA | Pyridinmethylenzolidinone und ihre verwendung als phosphoinositid-hemmer |
JP2006137723A (ja) | 2004-11-15 | 2006-06-01 | Kyowa Hakko Kogyo Co Ltd | スルホンアミド誘導体 |
US20090137558A1 (en) | 2004-12-03 | 2009-05-28 | Peakdale Molecular Limited | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US7592334B2 (en) | 2005-01-25 | 2009-09-22 | Glaxo Group Limited | Antibacterial agents |
US7709472B2 (en) | 2005-01-25 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
EP1846416A4 (de) | 2005-01-25 | 2009-07-01 | Glaxo Group Ltd | Antibakterielle wirkstoffe |
JP2008528598A (ja) | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
WO2006091395A2 (en) | 2005-02-14 | 2006-08-31 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
ES2456000T3 (es) | 2005-08-26 | 2014-04-21 | Merck Serono Sa | Derivados de pirazina y su uso como inhibidores de PI3K |
KR20140033237A (ko) | 2005-10-07 | 2014-03-17 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
-
2005
- 2005-11-11 EP EP05024692A patent/EP1790342A1/de not_active Withdrawn
-
2006
- 2006-10-11 UA UAA200807895A patent/UA95464C2/ru unknown
- 2006-11-10 EP EP06849272.7A patent/EP1962854B1/de active Active
- 2006-11-10 JP JP2008539444A patent/JP5448450B2/ja not_active Expired - Fee Related
- 2006-11-10 WO PCT/EP2006/068323 patent/WO2007079999A2/de active Application Filing
- 2006-11-10 TW TW095141709A patent/TWI423973B/zh not_active IP Right Cessation
- 2006-11-10 RU RU2008123219/15A patent/RU2487713C2/ru not_active IP Right Cessation
- 2006-11-10 ES ES06849272.7T patent/ES2543962T3/es active Active
- 2006-11-10 BR BRPI0618451-0A patent/BRPI0618451A2/pt not_active IP Right Cessation
- 2006-11-10 PL PL06849272T patent/PL1962854T3/pl unknown
- 2006-11-10 SG SG10201401061XA patent/SG10201401061XA/en unknown
- 2006-11-10 CA CA002628186A patent/CA2628186A1/en not_active Abandoned
- 2006-11-10 CN CN200680047112.6A patent/CN101330918B/zh not_active Expired - Fee Related
- 2006-11-10 US US11/558,493 patent/US8937068B2/en not_active Expired - Fee Related
- 2006-11-10 NZ NZ595879A patent/NZ595879A/xx unknown
- 2006-11-10 AU AU2006334721A patent/AU2006334721B2/en not_active Ceased
- 2006-11-13 AR ARP060104948A patent/AR056216A1/es unknown
-
2008
- 2008-04-25 ZA ZA200803867A patent/ZA200803867B/xx unknown
- 2008-04-30 IL IL191160A patent/IL191160A/en not_active IP Right Cessation
- 2008-06-03 NO NO20082509A patent/NO20082509L/no not_active Application Discontinuation
- 2008-06-11 KR KR1020087014066A patent/KR101473662B1/ko active IP Right Grant
-
2009
- 2009-03-12 HK HK09102357.4A patent/HK1125823A1/zh not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
WO2004104003A1 (de) * | 2003-05-23 | 2004-12-02 | Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
WO2004104002A1 (de) * | 2003-05-23 | 2004-12-02 | Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als kinase-inhibitoren |
WO2005007099A2 (en) * | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
WO2007054556A1 (de) * | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
Also Published As
Publication number | Publication date |
---|---|
HK1125823A1 (zh) | 2009-08-21 |
IL191160A0 (en) | 2008-12-29 |
WO2007079999A2 (de) | 2007-07-19 |
AU2006334721B2 (en) | 2011-08-11 |
KR20080068116A (ko) | 2008-07-22 |
EP1962854A2 (de) | 2008-09-03 |
US8937068B2 (en) | 2015-01-20 |
RU2008123219A (ru) | 2009-12-20 |
RU2487713C2 (ru) | 2013-07-20 |
NZ595879A (en) | 2013-07-26 |
ZA200803867B (en) | 2009-05-27 |
TW200736253A (en) | 2007-10-01 |
CA2628186A1 (en) | 2007-07-19 |
CN101330918A (zh) | 2008-12-24 |
TWI423973B (zh) | 2014-01-21 |
ES2543962T3 (es) | 2015-08-26 |
IL191160A (en) | 2016-03-31 |
PL1962854T3 (pl) | 2015-10-30 |
NO20082509L (no) | 2008-07-23 |
SG10201401061XA (en) | 2014-07-30 |
UA95464C2 (en) | 2011-08-10 |
EP1962854B1 (de) | 2015-05-06 |
BRPI0618451A2 (pt) | 2011-08-30 |
EP1790342A1 (de) | 2007-05-30 |
AU2006334721A1 (en) | 2007-07-19 |
JP5448450B2 (ja) | 2014-03-19 |
AR056216A1 (es) | 2007-09-26 |
CN101330918B (zh) | 2015-09-02 |
JP2009515854A (ja) | 2009-04-16 |
US20070123494A1 (en) | 2007-05-31 |
KR101473662B1 (ko) | 2014-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007079999A3 (de) | Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege | |
WO2006050965A8 (en) | Pyrimidine compounds as histamine modulators | |
WO2007109120A3 (en) | Imidazolothiazole compounds for the treatment of disease | |
WO2005012242A3 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
WO2008051416A3 (en) | Compounds that inhibit the activity of hsp90 for treating infections | |
WO2007064883A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2008067219A3 (en) | Quinazolinone modulators of tgr5 | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2007075869A3 (en) | Bicyclic heteroaryl compounds | |
WO2007149907A3 (en) | Pyrazoloquinazolinones as parp inhibitors | |
WO2010062396A3 (en) | Virus like particle compositions and methods of use | |
WO2007057768A3 (en) | Sulfonyl derivatives | |
WO2006076442A3 (en) | Triazolopyrimidine derivatives | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
WO2007009120A3 (en) | Heterotetracyclic compounds as tpo mimetics | |
WO2006078886A3 (en) | Compounds and compositions as wnt signaling pathway modulators | |
WO2007072201A3 (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
WO2010011331A3 (en) | Compositions and methods related to sirt1 function | |
WO2007022269A3 (en) | Compounds and compositions as tpo mimetics | |
WO2006076370A3 (en) | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions | |
WO2008005908A3 (en) | Pyridoimidazole derivatives | |
WO2006128143A3 (en) | Hydantoin compounds | |
WO2007050348A3 (en) | Potassium channel inhibitors | |
WO2007096703A3 (en) | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | |
WO2010019511A3 (en) | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680047112.6 Country of ref document: CN |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006849272 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191160 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2628186 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501052 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/006067 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2008539444 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006334721 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006334721 Country of ref document: AU Date of ref document: 20061110 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1121/MUMNP/2008 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006334721 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 568916 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008123219 Country of ref document: RU Ref document number: a200807895 Country of ref document: UA Ref document number: 1020087014066 Country of ref document: KR Ref document number: A20080759 Country of ref document: BY |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06849272 Country of ref document: EP Kind code of ref document: A2 |
|
WWP | Wipo information: published in national office |
Ref document number: 2006849272 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0618451 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080512 |